Hostname: page-component-745bb68f8f-grxwn Total loading time: 0 Render date: 2025-02-11T23:52:23.456Z Has data issue: false hasContentIssue false

Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999

Published online by Cambridge University Press:  20 July 2006

J. BOYDELL
Affiliation:
Division of Psychological Medicine, Institute of Psychiatry, London, UK
J. VAN OS
Affiliation:
Division of Psychological Medicine, Institute of Psychiatry, London, UK
A. CASPI
Affiliation:
Division of Psychological Medicine, Institute of Psychiatry, London, UK
N. KENNEDY
Affiliation:
Division of Psychological Medicine, Institute of Psychiatry, London, UK
E. GIOUROUKOU
Affiliation:
Division of Psychological Medicine, Institute of Psychiatry, London, UK
P. FEARON
Affiliation:
Division of Psychological Medicine, Institute of Psychiatry, London, UK
M. FARRELL
Affiliation:
Division of Psychological Medicine, Institute of Psychiatry, London, UK
R. M. MURRAY
Affiliation:
Division of Psychological Medicine, Institute of Psychiatry, London, UK
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background. There is evidence that cannabis use might be relevant to the aetiology of schizophrenia. We aimed to measure any change in cannabis use over time in those first presenting with schizophrenia in South-East London from 1965 to 1999, and compare this with change in use in those presenting with non-psychotic psychiatric disorders.

Method. The rate of cannabis use in the year prior to first ever presentation was measured over seven time periods. Logistic regression modelling was used to determine (a) whether cannabis use changed over time, after controlling for age, sex and ethnicity, and (b) whether there was an interaction between diagnosis and time.

Results. Cannabis use increased over time in both the schizophrenia group [odds ratio per time period (OR) 2·03, 95% confidence interval (CI) 1·74–2·38, p<0·0001] and the non-psychotic disorders group (OR 1·24, 95% CI 1·05–1·47, p=0·012), after controlling for age, sex and ethnicity. However, the effect of time was significantly greater in the schizophrenia group than in the non-schizophrenia group (χ2=17, p<0·0001).

Conclusion. Cannabis use in the year prior to presentation with schizophrenia increased markedly between 1965 and 1999, and disproportionately so compared to increase in cannabis use in other psychiatric disorders.

Type
Original Article
Copyright
2006 Cambridge University Press